NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisions FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the availability of PanTracer Pro, a new addition to the PanTracer® Family, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors.As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points. PanTracer Pro was developed to
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026Business Wire
- NeoGenomics: Distribution Moat In Community Oncology [Seeking Alpha]Seeking Alpha
- NeoGenomics (NASDAQ:NEO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- NeoGenomics (NASDAQ:NEO) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.MarketBeat
- NeoGenomics sees Q4 revenue of about $190M [Seeking Alpha]Seeking Alpha
NEO
Earnings
- 10/28/25 - Beat
NEO
Sec Filings
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- 1/15/26 - Form 4
- NEO's page on the SEC website